1992
Prevalence of Tuberculin Positivity and Skin Test Anergy in HIV-1—Seropositive and —Seronegative Intravenous Drug Users
Graham N, Nelson K, Solomon L, Bonds M, Rizzo R, Scavotto J, Astemborski J, Vlahov D. Prevalence of Tuberculin Positivity and Skin Test Anergy in HIV-1—Seropositive and —Seronegative Intravenous Drug Users. JAMA 1992, 267: 369-373. PMID: 1727959, DOI: 10.1001/jama.1992.03480030047035.Peer-Reviewed Original ResearchConceptsIntravenous drug usersHIV-1 seropositivesSkin test anergyHIV-1 seropositive groupSeronegative intravenous drug usersTuberculin positivityLymphocyte countPPD positivityHIV-1-seropositive intravenous drug usersPPD tuberculinDrug usersHuman immunodeficiency virus serostatusSeropositive intravenous drug usersHIV-1 seropositive patientsTuberculin skin test resultsHIV-1 seronegativeHIV-1 seronegativesPPD test resultsHIV-1 seropositivityDelayed-type hypersensitivityCommunity-based cohortSkin test resultsYears of agePositive test resultsInverse linear trend
1989
Immunological effects of HIV-1 infection on the humoral response to malaria in an African population.
Wabwire-Mangen F, Shiff C, Vlahov D, Kline R, Serwadda D, Sewankambo N, Mugerwa R, Quinn T. Immunological effects of HIV-1 infection on the humoral response to malaria in an African population. American Journal Of Tropical Medicine And Hygiene 1989, 41: 504-11. PMID: 2683820, DOI: 10.4269/ajtmh.1989.41.504.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdolescentAdultAnimalsAntibodies, ProtozoanAntigens, ProtozoanAntigens, SurfaceCross-Sectional StudiesEnzyme-Linked Immunosorbent AssayFemaleHIV SeropositivityHIV-1HumansMalariaMaleMiddle AgedPlasmodiumPlasmodium falciparumPlasmodium malariaeProtozoan ProteinsUgandaConceptsHIV-1 infectionTrauma patientsClinical AIDSSeronegative patientsAntibody levelsHIV-1HIV-1-seronegative patientsHIV-1 seropositive patientsPolyclonal B cell activationCross-sectional studyHigh malaria transmissionB cell stimulationB cell activationSeropositive patientsImmunodeficiency syndromeMalaria antibodiesHumoral responseImmunological effectsSerological responseStudy groupPatientsCell activationMalaria transmissionControl populationLess antibody